Klinische studies over pulmonale hypertensie

Actieve studies

ADVANCE OUTCOMES (NCT03626688): A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients (Ralinepag/placebo).
ADVANCE EXTENSION (NCT03683186): A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension.
COMPERA REGISTER (NCT01347216): Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension.
EXPOSURE Register.
INSIGNIA-PH-COPD (NCT05612035): A Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease.
PHOCUS (NCT06635850): A Study to Assess the Efficacy and Safety of Mosliciguat in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease.
PROSERA (NCT05934526): A Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of PAH.
SOTERIA (NCT04796337): An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension Therapy for the Treatment of PAH.
UNISUS (NCT04273945): Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension.

Toekomstige studies

C5001001 (NCT06137742): A Study to Learn How the Study Medicine Called PF-07868489 is Tolerated and Acts in Healthy Adult People and People With Pulmonary Arterial Hypertension.
C5001004: A phase 2, open-label extension study to investigate the safety and efficacy of PF-07868489 administered to adult participants with pulmonary arterial hypertension
CLTP001A12202: A Study to Evaluate the Efficacy and Safety of LTP001 for the Treatment of Participants with Pulmonary Arterial Hypertension
GO-CTEPH: Balloon pulmonary angioplasty versus pulmonary endarterectomy in patients with Chronic ThromboEmbolic Pulmonary Hypertension: a non-inferiority randomized trial
IRON-PH: A randomized, double-blind, placebo-controlled, multicentre trial, assessing the impact of ferric carboxymaltose on exercise capacity and functional status in pulmonary hypertension
PROSERA-EXT: An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Seralutinib Orally Inhaled for the Treatment of Pulmonary Arterial Hypertension (PAH).

Studies afgerond afgelopen 5 jaar

ADVANCE CAPACITY: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by Cardiopulmonary Exercise Testing in Subjects with World Health Organization Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
CADENCE: A Phase 2, Double-blind, Randomized, Placebocontrolled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF)
CIPHER: A Prospective, Multicenter Study for the Identification of Biomarker Signatures for early detection of Pulmonary Hypertension (PH)
ELEVATE II: A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension
HYPERION: Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients.
IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hypertension (PAH)
IMPAHCT-FUL: A Long-Term Extension, Multi-Center Safety Study of AV-101 in Subjects With Pulmonary Arterial Hypertension (PAH) Who Have Completed Study AV-101-002
INS1009-202: A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension
INS1009-211: A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease
INSIGNIA-PAH: A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension
PLATYPUS: A Prospective, Open-label, Platform Study for Long-term Follow-up of Participants Using Study Intervention in Pulmonary Hypertension Parent Studies
SALTO: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Event-Driven, Group-Sequential Study with Open-Label Extension Period to Assess the Efficacy and Safety of Selexipag as Add-On Treatment to Standard of Care in Children Aged ≥2 to
SELECT: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, group-sequential, adaptive, Phase 3 study with open-label extension period to assess the efficacy and safety of selexipag as an add-on to standard of care therapy in subjects with inoperable or persistent/recurrent after surgical and/or interventional treatment Chronic Thromboembolic Pulmonary Hypertension.
SPHINX: A Multicenter, Randomized, Double-blind, Placebo-controlled Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag
STELLAR: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
TORREY: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)
TORREY OLE: An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)
UMBRELLA: Multicenter, single-arm, open-label, long-term safety study with macitentan in patients with pulmonary hypertension previously treated with macitentan in clinical studies
ZENITH: A Phase 3, Randomized, Double-Blind, PlaceboControlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) World Health Organization (WHO) Functional Class (FC) III or FC IV at High Risk of Mortality